表紙:敗血症市場:2030年までの世界の医薬品予測と市場分析
市場調査レポート
商品コード
1039411

敗血症市場:2030年までの世界の医薬品予測と市場分析

Sepsis - Global Drug Forecast and Market Analysis to 2030

出版日: | 発行: GlobalData | ページ情報: 英文 177 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
敗血症市場:2030年までの世界の医薬品予測と市場分析
出版日: 2021年11月19日
発行: GlobalData
ページ情報: 英文 177 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

敗血症の市場規模は、2020年に34億8,000万米ドルとなりました。同市場は、今後8%のCAGRで拡大し、2030年には75億2,000万米ドルになると予測されています。7大市場の中では米国が最大市場であり、2020年には69.5%の市場シェアを占めました。これは、2030年には77%まで増加するとみられています。

当レポートでは、敗血症市場について調査し、敗血症の概要と疫学、アンメットニーズ、研究開発戦略とパイプライン評価などを提供しています。

目次

第1章 敗血症:エグゼクティブサマリー

第2章 イントロダクション

  • 促進要因
  • 関連レポート

第3章 病気の概要

  • 病因と病態生理学
    • 概要
    • 病因
    • 病態生理学
  • 分類または病期システム

第4章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界的および歴史的動向
  • 予測調査手法
    • 使用されたソース
    • 予測の前提条件と方法
    • 敗血症の診断済症例件数
    • 原因物質別敗血症診断済症例件数
    • 診断済症例件数における臓器機能不全
    • 敗血症の院内死亡症例
    • 敗血症性ショックの診断済症例件数
    • 原因物質別敗血症性ショックの診断済症例件数
    • 敗血症性ショックの診断済症例件数における臓器機能障害

第5章 疾病管理

  • 診断と治療の概要
  • 治療ガイドライン
  • 敗血症の臨床管理
    • 全身性炎症反応症候群
    • 敗血症
    • 敗血症性ショック
    • 多臓器不全症候群
    • 院内敗血症:医療関連および院内感染
    • 新生児敗血症
  • 治療クラス別の上市薬
    • 抗生物質
    • その他の抗感染薬
    • 昇圧剤と循環作動薬
    • 抗凝固剤
    • 免疫調節剤
  • 敗血症治療のための非薬物療法的手段
    • 機械的換気
    • 血液透析
    • 輸液蘇生
    • 血液製剤管理
    • 敗血症患者のための栄養調節
  • 地域別敗血症の治療
    • 米国
    • EU5か国
    • 日本
  • 疾病管理に関するKOLの洞察

第6章 競争力評価

  • 概要

第7章 アンメットニーズと機会の評価

  • 概要
  • 公衆およびヘルスケア専門家のための敗血症教育および意識の向上
  • 敗血症の早期認識と治療
  • 敗血症誘発性併存疾患に対する改善された支持療法
  • 敗血症の病態生理学の理解の向上

第8章 研究開発戦略

  • 概要
  • 多様な作用機序を持つ敗血症治療薬の開発
    • 凝固システム
    • 内皮
    • 臓器障害
    • 宿主免疫反応
  • 同様の適応症に対する既存の市販薬のラベル拡大
  • コラボレーション、ライセンシング、およびパートナーシップ
  • 臨床試験デザイン
    • 敗血症の創薬候補者のための現在の臨床試験デザイン
    • 敗血症の創薬候補者のための現在の臨床試験デザインに関する問題

第9章 パイプライン評価

  • 概要
  • 臨床開発における有望な薬剤
  • 臨床試験
  • 初期段階のパイプラインエージェント

第10章 パイプライン評価分析

  • 概要
  • 主要なパイプライン薬の臨床ベンチマーク
  • 主要なパイプライン薬の商業的ベンチマーク
  • 競争力評価

第11章 現在および将来の参入企業

第12章 市場の見通し

第13章 付録

図表

List of Tables

List of Tables

  • Table 1: Sepsis: Key Metrics in the 7MM
  • Table 2: Stages of Sepsis, According to SSC Guidelines
  • Table 3: Risk Factors and Comorbidities for Sepsis and Septic Shock
  • Table 4: Criteria Used for SOFA Score in the Diagnosis of Sepsis
  • Table 5: Treatment Guidelines for Sepsis in the 7MM
  • Table 6: Commonly Used Antibiotics in Sepsis and Septic Shock and Corresponding Gaps in Coverage
  • Table 7: Examples of Supportive Therapies for Patients with Sepsis or Septic Shock
  • Table 8: Sepsis Disease Management - US
  • Table 9: Sepsis Disease Management - 5EU
  • Table 10: Sepsis Disease Management - Japan
  • Table 11: Marketed Therapies for Sepsis Across the 7MM
  • Table 12: Collaboration, Licensing and Deals of Sepsis Drug Candidates
  • Table 13: Clinical Trial Designs for Sepsis Pipeline Drug Candidates
  • Table 14: Innovative Early-Stage Approaches for Sepsis, 2021
  • Table 15: Clinical Benchmark of Key Marketed and Pipeline Drugs - Immunomodulators in Sepsis
  • Table 16: Clinical Benchmark of Key Marketed and Pipeline Drugs - Vasopressors in Sepsis
  • Table 17: Clinical Benchmark of Key Marketed and Pipeline Drugs - Antimicrobials in Sepsis
  • Table 18: Clinical Benchmark of Key Marketed and Pipeline Drugs - Fluid Therapy in Sepsis
  • Table 19: Commercial Benchmark of Key Marketed and Pipeline Drugs - Immunomodulators in Sepsis
  • Table 20: Commercial Benchmark of Key Marketed and Pipeline Drugs - Vasopressors in Sepsis
  • Table 21: Commercial Benchmark of Key Marketed and Pipeline Drugs - Antimicrobials in Sepsis
  • Table 22: Commercial Benchmark of Key Marketed and Pipeline Drugs - Fluid Therapy in Sepsis
  • Table 23: Adrenomed's Sepsis Portfolio Assessment, 2021
  • Table 24: AM-Pharma's Sepsis Portfolio Assessment, 2021
  • Table 25: Asahi Kasei Pharma's Sepsis Portfolio Assessment, 2021
  • Table 26: Grifols' Sepsis Portfolio Assessment, 2021
  • Table 27: Inotrem's Sepsis Portfolio Assessment, 2021
  • Table 28: La Jolla's Sepsis Portfolio Assessment, 2021
  • Table 29: Merck's Sepsis Portfolio Assessment, 2021
  • Table 30: Pfizer's Sepsis Portfolio Assessment, 2021
  • Table 31: RevImmune's Sepsis Portfolio Assessment, 2021
  • Table 32: Sanofi's Sepsis Portfolio Assessment, 2021
  • Table 33: Takeda's Sepsis Portfolio Assessment, 2021
  • Table 34: Sepsis Market - Global Drivers and Barriers, 2020-2030
  • Table 35: Key Events Impacting Sales for Sepsis in the US, 2020-2030
  • Table 36: Sepsis Market - Drivers and Barriers in the US, 2020-2030
  • Table 37: Key Events Impacting Sales for Sepsis in the 5EU, 2020-2030
  • Table 38: Sepsis Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 39: Key Events Impacting Sales for Sepsis in Japan, 2020-2030
  • Table 40: Sepsis Market - Drivers and Barriers in Japan, 2020-2030
  • Table 41: Key Projected Launch Dates for Sepsis and Septic Shock
  • Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Sepsis in 2020 and 2030
  • Figure 2: Company Portfolio Gap Analysis in Sepsis During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period
  • Figure 4: Pathophysiological Features of Sepsis
  • Figure 5: 7MM, Diagnosed Incidence of Sepsis, All Ages, Men and Women, Cases per 100,000 Population, 2010-2030
  • Figure 6: 7MM, Diagnosed Incidence of Septic Shock, All Ages, Men and Women, Cases per 100,000 Population, 2010-2030
  • Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Incident Cases of Sepsis
  • Figure 8: 7MM, Sources Used for the Diagnosed Incident Cases of Septic Shock
  • Figure 9: 7MM, Sources Used for the Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agents
  • Figure 10: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Sepsis
  • Figure 11: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Septic Shock
  • Figure 12: 7MM, Sources Used and Not Used for Sepsis/Septic Shock In-Hospital Mortality Cases
  • Figure 13: Overview of Treatment Options for Sepsis and Septic Shock
  • Figure 14: Unmet Needs and Opportunities in Sepsis and Septic Shock
  • Figure 15: Overview of the Global Development Pipeline in Sepsis
  • Figure 16: Key Clinical Trials for Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Sepsis During the Forecast Period
  • Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period
  • Figure 18: Competitive Assessment of RecAP and CYT107, the Pipeline Therapies for Immunomodulation in Sepsis, Benchmarked against the SOCs, Hydrocortisone and IVIg
  • Figure 19: Competitive Assessment of Motrem and Adrecizumab, the Pipeline Therapies for Vasopressors in Sepsis, Benchmarked against the SOC, Norepinephrine
  • Figure 20: Competitive Assessment of Cefiderocol, the Pipeline Therapy for Antimicrobials in Sepsis, Benchmarked against the SOC, Meropenem
  • Figure 21: Competitive Assessment of Human Albumin, the Pipeline Therapy for Fluid Therapy in Sepsis, Benchmarked against the SOC, Ringer's lactate
  • Figure 22: Company Portfolio Gap Analysis in Sepsis, 2020-2030
  • Figure 23: Global (7MM) Sales Forecast by Country for Sepsis in 2020 and 2030
  • Figure 24: Sales Forecast by Class for Sepsis in the US in 2020 and 2030
  • Figure 25: Sales Forecast by Class for Sepsis in the 5EU in 2020 and 2030
  • Figure 26: Sales Forecast by Class for Sepsis in Japan in 2020 and 2030
目次
Product Code: GDHC226PIDR

Sepsis is a life-threatening condition that occurs when the body's response to an infection causes injury to its own tissues and organs. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure, and death, and is most frequently a serious complication of infection. Sepsis is the leading cost of death in hospitals, and accounts for one in five deaths globally. The current treatment of sepsis is antibiotics and supportive therapy, such as immunomodulators, vasopressors and fluid resuscitation. There has been little development in the sepsis therapeutic market, with only two drugs being approved in the last twenty years. The sepsis market is currently dominated by generic drugs.

GlobalData projects the global (7MM) sepsis to experience high growth during the forecast period. There are 6 products expected to launch in the 7MM by 2030. The launch of Revimmune's recombinant human interlukin-7 CYT107, AM-Pharma's recombinant phosphatase recAP, and Adrenomed's adrecizumab will be key drivers of growth. The launch of several biologics that target the cause of sepsis itself will fulfill a major unmet need, and will have a significant effect on the overall size of the sepsis market.

The sepsis market is expected to grow from $3.48B in 2020 to $7.52B in 2030, a CAGR of 8%. The US is the biggest market of the 7MM, accounting for 69.5% market share in 2020. This is set to increase to 77% by 2030. During the 10-year forecast period, there are six major pipeline products that are on track to launch which will drive the majority of growth in this market.

Key Questions Answered

  • How will the sepsis market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2020-2030?
  • What are the most promising late-stage pipeline products for sepsis?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing sepsis treatment options?
  • What are the remaining unmet needs in sepsis therapeutics?
  • What drivers and barriers will affect sepsis therapy sales in the 7MM over the forecast period?

Scope

  • Overview of sepsis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline sepsis theraputic market revenue from 2020-2030. Annual cost of therapy and major pipeline product sales in this forecast period are included.
  • Key topics covered include current sepsis therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global sepsis therapeutic market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global sepsis therapeutic market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis therapeutic market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Sepsis: Executive Summary

  • 1.1 Sepsis Treatment to Experience Strong Growth over the Forecast Period from 2020-2030
  • 1.2 Developers Must Leverage Innovative R&D Strategies to Target Appropriate Patients and Achieve Sustained Commercial Success
  • 1.3 A High Level of Unmet Need Persists in the Sepsis and Septic Shock Marketplace
  • 1.4 Opportunities Remain for Current and Future Players to Develop Therapies Targeting Sepsis-Specific Pathophysiology
  • 1.5 Immunomodulating Therapies Poised to Transform Sepsis and Septic Shock Market, but Missing Biomarkers Will Limit Their Utility
  • 1.6 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Overview
    • 3.1.2 Etiology
    • 3.1.3 Pathophysiology
  • 3.2 Classification or Staging Systems

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 Forecast Methodology
    • 4.4.1 Sources Used
    • 4.4.2 Forecast Assumptions and Methods
    • 4.4.3 Diagnosed Incident Cases of Sepsis
    • 4.4.4 Diagnosed Incident Cases of Sepsis by Causative Agent
    • 4.4.5 Organ Dysfunction in Diagnosed Incident Cases of Sepsis
    • 4.4.6 Sepsis In-Hospital Mortality Cases
    • 4.4.7 Diagnosed Incident Cases of Septic Shock
    • 4.4.8 Diagnosed Incident Cases of Septic Shock by Causative Agent
    • 4.4.9 Organ Dysfunction in Diagnosed Incident Cases of Septic Shock

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 Treatment Guidelines
  • 5.3 Clinical Management of Sepsis
    • 5.3.1 Systemic Inflammatory Response Syndrome
    • 5.3.2 Sepsis
    • 5.3.3 Septic Shock
    • 5.3.4 Multiple Organ Dysfunction Syndrome
    • 5.3.5 Nosocomial Sepsis: Healthcare-Associated and Hospital-Acquired
    • 5.3.6 Neonatal Sepsis
  • 5.4 Marketed Drugs by Therapeutic Class
    • 5.4.1 Antibiotics
    • 5.4.2 Other Anti-infective Agents
    • 5.4.3 Vasopressors and Inotropes
    • 5.4.4 Anticoagulants
    • 5.4.5 Immunomodulators
  • 5.5 Non-pharmacotherapeutic Measures for the Treatment of Sepsis
    • 5.5.1 Mechanical Ventilation
    • 5.5.2 Hemodialysis
    • 5.5.3 Fluid Resuscitation
    • 5.5.4 Blood Product Administration
    • 5.5.5 Nutritional Accommodations for Septic Patients
  • 5.6 Treatment of Sepsis by Geographic Region
    • 5.6.1 US
    • 5.6.2 5EU
    • 5.6.3 Japan
  • 5.7 Key Opinion Leader Insights on Disease Management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Improved Sepsis Education and Awareness for the Public and Healthcare Professionals
  • 7.3 Early Recognition and Treatment of Sepsis
  • 7.4 Improved Supportive Care for Sepsis-Induced Comorbidities
  • 7.5 Improved Understanding of Sepsis Pathophysiology

8 R&D Strategies

  • 8.1 Overview
  • 8.2 Development of Sepsis Therapeutics with Diverse Mechanisms of Action
    • 8.2.1 Coagulation System
    • 8.2.2 Endothelium
    • 8.2.3 Organ Damage
    • 8.2.4 Host Immune Response
  • 8.3 Label Expansion of Existing Marketed Drugs for Similar Indications
  • 8.4 Collaboration, Licensing, and Partnerships
  • 8.5 Clinical Trial Design
    • 8.5.1 Current Clinical Trial Designs for Sepsis Drug Candidates
    • 8.5.2 Issues with Current Clinical Trial Design for Sepsis Drug Candidates

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
  • 9.3 Clinical Trials
  • 9.4 Early-Stage Pipeline Agents

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Clinical Benchmark of Key Pipeline Drugs
    • 10.2.1 Clinical Benchmarking of Immunomodulators
    • 10.2.2 Clinical Benchmarking of Vasopressors
    • 10.2.3 Clinical Benchmarking of Antimicrobials
    • 10.2.4 Clinical Benchmarking of Fluid Therapy
  • 10.3 Commercial Benchmark of Key Pipeline Drugs
    • 10.3.1 Commercial Benchmarking of Immunomodulators
    • 10.3.2 Commercial Benchmarking of Vasopressors
    • 10.3.3 Commercial Benchmarking of Antimicrobials
    • 10.3.4 Commercial Benchmarking of Fluid Therapies
  • 10.4 Competitive Assessment
    • 10.4.1 Competitive Assessment of Immunomodulators
    • 10.4.2 Competitive Assessment of Vasopressors
    • 10.4.3 Competitive Assessment of Antimicrobials
    • 10.4.4 Competitive Assessment of Fluid Therapy

11 Current and Future Players

12 Market Outlook

13 Appendix